FindTrial
Sign In

Neoadjuvant Immunotherapy combined with Chemotherapy in the treatment of Resectable Thoracic Esophageal Squamous Cell Cancer (NICE) with multiple lymph-node stations metastasis: an exploring phase II study

Neoadjuvant Immunotherapy combined with Chemotherapy in Resectable Thoracic Esophageal Squamous Cell Cancer (NICE) with multiple lymph-node stations metastasis: an exploring phase II study

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026240
Enrollment
Unknown
Registered
2019-09-28
Start date
2019-10-08
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

single group:camrelizumab

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. signed informed consent; 2. patients age 18 and older; 3. primary resectable, histologically confirmed esophageal squamous cell cancer; 4. multiple lymph-nodes metastasis; 5. ECOG PS 0-1.

Exclusion criteria

Exclusion criteria: 1. with significant cardiovascular disease; 2. current treatment with anti-viral therapy or HBV; 3. pregnancy or breastfeeding; 4. history of malignancy within 3 years prior to screening; 5. active or history of autoimmune disease or immune deficiency; 6. signs of distant metastases.

Design outcomes

Primary

MeasureTime frame
Pathologic complete response rate;—

Secondary

MeasureTime frame
R0 resection rate;—

Countries

China

Contacts

Public ContactLiu Jun

Shanghai Chest Hospital

drjunliu@qq.com+86 18930859538

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026